Abstract
The administration of therapeutic proteins via the subcutaneous route (sc) is desired for compliance and convenience, but could be challenging due to perceived immunogenic potential or unwanted immune responses. There are clinical and preclinical data supporting as well as refuting the generalized notion that sc is more immunogenic. We provide a mechanistic perspective of immunogenicity of therapeutic proteins administered via the sc route and discuss strategies and opportunities for novel therapeutic approaches to mitigate immunogenicity.
| Original language | English |
|---|---|
| Pages (from-to) | 897-900 |
| Number of pages | 4 |
| Journal | AAPS PharmSci |
| Volume | 15 |
| Issue number | 4 |
| DOIs | |
| State | Published - 2013 |
Keywords
- biotechnology
- immunogenicity
- mitigation of immunogenicity
- protein therapeutics
- subcutaneous administration
Fingerprint
Dive into the research topics of 'Immunogenicity of subcutaneously administered therapeutic proteins - A mechanistic perspective'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver